市场调查报告书
商品编码
1468336
2024-2032 年经导管主动脉瓣植入市场(依手术、最终使用者和地区划分)Transcatheter Aortic Valve Implantation Market by Procedure, End User, and Region 2024-2032 |
2023年全球经导管主动脉瓣植入术(TAVI)IMARC Group规模达63亿美元。 10.65% 。冠状动脉疾病的盛行率不断上升、微创疗法的日益普及以及老年人口的不断扩大是推动市场发展的一些关键因素。
经导管主动脉瓣植入术(TAVI) 是一种用于治疗主动脉瓣狭窄的微创外科手术,主动脉瓣狭窄是一种心臟疾病,主动脉瓣变窄,导致从心臟到身体其他部位的血流量减少。在手术过程中,会在患者的腹股沟或胸部切一个小切口。插入导管并引导其穿过股动脉或主动脉到达狭窄的主动脉瓣。由生物材料(例如动物组织或合成材料)製成的人工瓣膜会透过导管展开并定位在狭窄的瓣膜内,该瓣膜会膨胀以取代旧的瓣膜,使血液能够从心臟自由流动。 TAVI 可在局部麻醉下进行。与传统手术相比,它的恢復时间更短,併发症风险更低,适合因病重或虚弱而无法进行心臟直视手术的患者。
越来越多的患者患有心臟衰竭、高血压、冠状动脉疾病和心血管疾病(CVD),特别是主动脉瓣狭窄,这主要推动了经导管主动脉瓣植入(TAVI)市场的成长。除此之外,由于微创手术(MIS) 具有减少住院时间、缩短復健时间、改善结果和降低整体医疗保健支出等优势,消费者对微创手术(MIS) 的偏好相对于传统心臟直视手术的转变正在创造积极的前景。此外,消费者对主动脉瓣疾病和可用治疗方案的认识不断提高,从而实现早期诊断和及时治疗,这有助于市场成长。除此之外,研发 (R&D) 计画的大量资金以及 TAVI 手术中持续的技术进步(例如生物瓣膜、自膨胀瓣膜和其他创新设备的开发)正在加强市场成长。此外,医疗保健产业的强劲成长、临床试验数量的增加、产品的持续创新、老年人口的不断扩大以及有利的报销政策都为市场带来了丰厚的成长机会。
The global transcatheter aortic valve implantation (TAVI) market size reached US$ 6.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 16.1 Billion by 2032, exhibiting a growth rate (CAGR) of 10.65% during 2024-2032. The increasing prevalence of coronary artery disease, the rising adoption of minimally invasive therapies, and the expanding geriatric population represent some of the key factors driving the market.
Transcatheter Aortic Valve Implantation (TAVI) refers to a minimally invasive surgical procedure used to treat aortic stenosis, a heart condition in which the aortic valve narrows, resulting in reduced blood flow from the heart to the rest of the body. During the procedure, a small incision is made in the patient's groin or chest. A catheter is inserted and guided through the femoral artery or the aorta to the narrowed aortic valve. An artificial valve made of biological material, such as animal tissue or synthetic materials, is deployed through the catheter and positioned inside the narrowed valve, which expands to replace the old valve, allowing blood to flow freely from the heart. TAVI can be performed under local anesthesia. Compared to traditional surgery, it has a shorter recovery time and a lower risk of complications and can be performed on patients who are too ill or frail to undergo open-heart surgery.
The growing number of patients suffering from heart failure, hypertension, coronary artery disease, and cardiovascular diseases (CVDs), particularly aortic stenosis, is primarily driving the transcatheter aortic valve implantation (TAVI) market growth. Besides this, the shifting consumer preference for minimally invasive surgery (MIS) over conventional open-heart surgery due to its advantages, such as reduced hospital stay, shorter recovery time, improved outcomes, and lower overall healthcare spending, is creating a positive outlook for the market. Moreover, the escalating consumer awareness about aortic valve disease and available treatment options leading to early diagnosis and timely treatment is contributing to the market growth. In addition to this, the extensive funding in research and development (R&D) initiatives and ongoing technological advancements in the TAVI procedure, such as the development of bioprosthetic valves, self-expanding valves, and other innovative devices, are strengthening the market growth. Furthermore, the bolstering growth of the healthcare industry, the increasing number of clinical trials, continuous product innovations, the expanding geriatric population, and favorable reimbursement policies are presenting remunerative growth opportunities for the market.
IMARC Group provides an analysis of the key trends in each segment of the global transcatheter aortic valve implantation (TAVI) market, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on procedure and end user.
Transfemoral Procedure
Transapical Implantation
Transaortic Implantation
The report has provided a detailed breakup and analysis of the transcatheter aortic valve implantation (TAVI) market based on the procedure. This includes the transfemoral procedure, transapical implantation, and transaortic implantation. According to the report, transfemoral procedure represented the largest segment.
Hospitals
Diagnostic Labs
Ambulatory Surgical Centers
Clinics
Others
A detailed breakup and analysis of the transcatheter aortic valve implantation (TAVI) market based on the end user has also been provided in the report. This includes hospitals, diagnostic labs, ambulatory surgical centers, clinics, and others. According to the report, hospitals accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for transcatheter aortic valve implantation (TAVI). Some of the factors driving the North America transcatheter aortic valve implantation (TAVI) market included the expanding prevalence of cardiovascular diseases, the rising adoption of minimally invasive therapies, and ongoing technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global transcatheter aortic valve implantation (TAVI) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences Corporation, JC Medical Inc. (Genesis Medtech International Private Limited), Medtronic plc, Meril Life Sciences Pvt. Ltd., NVT AG (Biosensors International Group), Venus Medtech (Hangzhou) Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.